DDInter1835 DDInter1840
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Topotecan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Topotecan {u} (Compound) downregulates {v} (Gene) RAF1
RAF1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) upregulates {v} (Gene) TERT
TERT {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) downregulates {v} (Gene) BAG3
BAG3 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) upregulates {v} (Gene) HLA-A
HLA-A {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) covaries with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Topotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Topotecan (Compound) downregulates RAF1 (Gene) and RAF1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) upregulates TERT (Gene) and TERT (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) upregulates HLA-A (Gene) and HLA-A (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Topotecan (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) covaries with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)